scholarly journals Advances of systemic treatment for adult soft-tissue sarcoma

2018 ◽  
Vol 7 (4) ◽  
pp. 42-42 ◽  
Author(s):  
Wenshuai Liu ◽  
Quan Jiang ◽  
Yuhong Zhou
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Systemic Treatment

scholarly journals Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan

2020 ◽  
Vol Volume 14 ◽  
pp. 4215-4220
Author(s):  
Tomoki Nakamura ◽  
Kunihiro Asanuma ◽  
Tomohito Hagi ◽  
Akihiro Sudo
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Clinical Outcome ◽  
Systemic Treatment ◽  
Real Life ◽  
Advanced Soft Tissue Sarcoma

Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies

2014 ◽  
Vol 11 (4) ◽  
pp. 187-202 ◽  
Author(s):  
Mark Linch ◽  
Aisha B. Miah ◽  
Khin Thway ◽  
Ian R. Judson ◽  
Charlotte Benson
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Gold Standard ◽  
Systemic Treatment ◽  
Novel Therapies

scholarly journals Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease

2014 ◽  
Vol 37 (6) ◽  
pp. 355-362 ◽  
Author(s):  
Patrick Schöffski ◽  
Jasmien Cornillie ◽  
Agnieszka Wozniak ◽  
Haifu Li ◽  
Daphne Hompes
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Systemic Treatment ◽  
Advanced Disease ◽  
Treatment Options

scholarly journals Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression

2021 ◽  
pp. 459-465
Author(s):  
Maggie Zhou ◽  
Nam Bui ◽  
Marta Lohman ◽  
Matt van de Rjin ◽  
Gloria Hwang ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Systemic Treatment ◽  
Checkpoint Inhibitor ◽  
Inhibitor Therapy ◽  
Genetic Mutations ◽  
Advanced Soft Tissue Sarcoma ◽  
Solid Malignancies ◽  
Checkpoint Inhibitor Therapy

Checkpoint inhibitor therapy has been shown to improve outcomes in multiple solid malignancies; however, data are limited in soft tissue sarcoma. We present two cases of patients with advanced soft tissue sarcoma of different subtypes (dedifferentiated liposarcoma and myxofibrosarcoma) with zero percent PD-L1 expression by immunohistochemistry who were treated with ipilimumab and nivolumab followed by maintenance nivolumab. Both patients had failed multiple lines of systemic treatment and experienced long-term remission after starting ipilimumab and nivolumab. Genetic testing revealed that no genetic mutations were found in common between the two cases. One patient received concurrent cryoablation, which may have sensitized his tumor to immunotherapy. Checkpoint inhibitor therapy may improve outcomes in soft tissue sarcoma regardless of PD-L1 status, especially when combined with cryoablation. Studies are needed to evaluate whether treatment response varies by sarcoma subtype and what molecular markers can be used to guide patient selection.

scholarly journals Chemotherapy in Pediatric-Type Soft-Tissue Sarcomas

2020 ◽  
Vol 26 ◽  
Author(s):  
K. M. Ingley ◽  
S. Cohen-Gogo ◽  
A. A. Gupta
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Alternative Treatment ◽  
Systemic Treatment ◽  
Treatment Options ◽  
Soft Tissue Sarcomas ◽  
Targeted Agents ◽  
Soft Tissue Tumours ◽  
Cooperative Approach ◽  
Multi Agent

Soft-tissue sarcoma (STS) is rare and represents approximately 7% of cancers in children and in adolescents less than 20 years of age. Rhabdomyosarcoma (RMS) is most prevalent in children less than 10 years of age and peaks again during adolescence (16–19 years of age). Multi-agent chemotherapy constitutes the mainstay of treatment for RMS. In other non-rhabdomyosarcoma soft-tissue tumours, such as synovial sarcoma, evidence for routine use of chemo-therapy is less robust, and alternative treatment options, including targeted agents and immunotherapy, are being explored. In this review, we focus on chemotherapy for pediatric-type RMS and discuss the advances and challenges in systemic treatment for select non-rhabdomyosarcoma soft-tissue tumours in children and adolescents. We  support an increasingly cooperative approach for treating pediatric and adult STS.

scholarly journals Advanced Soft Tissue Sarcoma: Systemic Treatment Patterns and Survival in Germany

2016 ◽  
Vol 19 (7) ◽  
pp. A760 ◽  
Author(s):  
DS Mytelka ◽  
M Lorenzo ◽  
D Stafkey-Mailey ◽  
Y D'Yachkova ◽  
SP Nagar ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Systemic Treatment ◽  
Treatment Patterns ◽  
Advanced Soft Tissue Sarcoma

scholarly journals Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new

BMC Medicine ◽  
2017 ◽  
Vol 15 (1) ◽  
Author(s):  
Anna Maria Frezza ◽  
Silvia Stacchiotti ◽  
Alessandro Gronchi
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Systemic Treatment ◽  
Advanced Soft Tissue Sarcoma

scholarly journals Systemic Therapy in Pediatric-Type Soft-Tissue Sarcoma

2020 ◽  
Vol 27 (11) ◽  
pp. 6-16
Author(s):  
K.M. Ingley ◽  
S. Cohen-Gogo ◽  
A.A. Gupta
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Alternative Treatment ◽  
Systemic Therapy ◽  
Systemic Treatment ◽  
Treatment Options ◽  
Targeted Agents ◽  
Soft Tissue Tumours ◽  
Cooperative Approach ◽  
Multi Agent

Soft-tissue sarcoma (sts) is rare and represents approximately 7% of cancers in children and in adolescents less than 20 years of age. Rhabdomyosarcoma (rms) is most prevalent in children less than 10 years of age and peaks again during adolescence (16–19 years of age). Multi-agent chemotherapy constitutes the mainstay of treatment for rms. In other non-rhabdomyosarcoma soft-tissue tumours, such as synovial sarcoma, evidence for routine use of chemotherapy is less robust, and alternative treatment options, including targeted agents and immunotherapy, are being explored. In this review, we focus on chemotherapy for pediatric-type rms and discuss the advances and challenges in systemic treatment for select non-rhabdomyosarcoma soft-tissue tumours in children and adolescents. We support an increasingly cooperative approach for treating pediatric and adult sts.

Sign in / Sign up

Export Citation Format

Share Document